Document 0253
 DOCN  M95B0253
 TI    Protection of macaques against simian immunodeficiency virus infection
       with inactivated vaccines: comparison of adjuvants, doses and challenge
       viruses. The European Concerted Action on 'Macaque Models for AIDS
       Research'.
 DT    9511
 SO    Vaccine. 1995 Feb;13(3):295-300. Unique Identifier : AIDSLINE
       MED/95358023
 AB    Nine European laboratories contributed a total of 98 macaques towards a
       collaborative trial to study the ability of formaldehyde-inactivated or
       subunit SIV vaccines to protect immunized animals against live virus
       challenges. Four adjuvants, three dose levels and two immunization
       schedules were compared. Fifty-two of 61 (85%) immunized animals were
       protected against infection after challenge with either homologous or
       heterologous virus strains grown in human cells. Optimum protection
       required a high dose of antigen and a prolonged immunization schedule.
       On the day of challenge the titres of antibodies to SIV and to host cell
       components, as well as the titres of neutralizing antibodies, were
       significantly higher in the protected animals than in the non-protected.
       Forty-four vaccinated macaques (of which 36 were protected against
       previous challenges grown in human cells) and 28 naive animals were then
       challenged with extracellular or cell-associated SIV grown in simian
       cells. All naive animals and all vaccinees challenged with extracellular
       SIV became infected. Four of the eight animals challenged with
       cell-associated viruses were protected. These results clearly indicate
       that vaccines which potently protect against SIV grown in human cells,
       do not protect against SIV grown in simian cells. The cell substrate on
       which challenge viruses are grown is clearly significant in interpreting
       the results of vaccine trials. This trial has demonstrated that SIV
       vaccines using different adjuvants can protect macaques against SIV
       grown in human cells but not against extracellular SIV grown in simian
       cells. These results have important relevance to the development of HIV
       vaccines for humans.(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Adjuvants, Immunologic/*THERAPEUTIC USE  Animal  Comparative Study
       Dose-Response Relationship, Drug  Female  Formaldehyde  Human
       Immunization Schedule  Macaca fascicularis  Macaca mulatta  Male  Simian
       Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL  Support,
       Non-U.S. Gov't  *SAIDS Vaccines/ADMINISTRATION & DOSAGE  SIV/GROWTH &
       DEVELOPMENT/IMMUNOLOGY  *Vaccines, Inactivated/ADMINISTRATION & DOSAGE
       JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).